No photo of Heikki Kuusanmäki

Heikki Kuusanmäki

20122019
If you made any changes in Pure these will be visible here soon.

International and National Collaboration Publications and projects within past five years.

Publications 2012 2019

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia

Kuusanmäki, H., Leppä, A-M., Pölönen, P., Kontro, M., Dufva, O., Deb, D., Yadav, B., Bruck, O., Kumar, A., Everaus, H., Gjertsen, B. T., Heinäniemi, M., Porkka, K., Mustjoki, S. & Heckman, C., 11 Jul 2019, In : Haematologica.

Research output: Contribution to journalArticleScientificpeer-review

Open Access
File

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target

Dufva, O., Kankainen, M., Kelkka, T., Sekiguchi, N., Awad, S. A., Eldfors, S., Yadav, B., Kuusanmäki, H., Malani, D., Andersson, E. I., Pietarinen, P., Saikko, L., Kovanen, P. E., Ojala, T., Lee, D. A., Loughran, T. P., Nakazawa, H., Suzumiya, J., Suzuki, R., Ko, Y. H. & 7 othersKim, W. S., Chuang, S-S., Aittokallio, T., Chan, W. C., Ohshima, K., Ishida, F. & Mustjoki, S., 19 Apr 2018, In : Nature Communications. 9, 12 p., 1567.

Research output: Contribution to journalArticleScientificpeer-review

Open Access
File

Targeting key survival signaling pathways for the treatment of leukemia

Kuusanmäki, H., 2018, Helsinki : [H. Kuusanmäki]. 88 p.

Research output: ThesisDoctoral ThesisCollection of Articles

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors

Pietarinen, P. O., Eide, C. A., Ayuda-Duran, P., Potdar, S., Kuusanmaki, H., Andersson, E. I., Mpindi, J. P., Pemovska, T., Kontro, M., Heckman, C. A., Kallioniemi, O., Wennerberg, K., Hjorth-Hansen, H., Druker, B. J., Enserink, J. M., Tyner, J. W., Mustjoki, S. & Porkka, K., 4 Apr 2017, In : Oncotarget. 8, 14, p. 22606-22615 10 p.

Research output: Contribution to journalArticleScientificpeer-review

Open Access

Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling

Kuusanmäki, H., Dufva, O., Parri, E., van Adrichem, A. J., Rajala, H., Majumder, M. M., Yadav, B., Parsons, A., Chan, W. C., Wennerberg, K., Mustjoki, S. & Heckman, C. A., 14 Nov 2017, In : Oncotarget. 8, 57, p. 97516-97527 12 p.

Research output: Contribution to journalArticleScientificpeer-review

Open Access
File

Activities 2018 2018

  • 1 Supervisor or co-supervisor of doctoral thesis

Targeting key survival signaling pathways for the treatment of leukemia

Caroline Heckman (Supervisor)
28 Sep 2018

Activity: Examination typesSupervisor or co-supervisor of doctoral thesis